Two cardiometabolic-related news items have been observed: Lifescan and Fitbit announced a multi-year collaboration for data integration into each other’s apps; and Sigilon announced its Q2 ’21 earnings. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed: Viatris and Senseonics hosted their respective Q2 ’21 earnings calls; AstraZeneca announced EU approval of Forxiga for the treatment of CKD in adults with and without T2DM; GoodRx and BI announced an initiative to increase access to cost-savings programs for patients with T2DM and COPD; Diamyd announced the European Patent Office has granted the Diamyd’s recent patent application for treatment using GAD; and Glooko announced Prakash Menon has been appointed as the company’s Chief Technology Officer. Below, FENIX provides highlights and insights for the respective news items.
Xeris, Amarin, Regeneron, and BD hosted their respective Q2 ’21 earnings calls, Below, FENIX provides highlights and insights from the events.
Insulet (press release), Provention Bio (press release), and Bayer (press release; slides) hosted their respective Q2 ’21 earnings calls. Importantly, Insulet disclosed the projected Omnipod 5 FDA clearance and launch have been delayed. Below, FENIX provides highlights and insights from the calls.
Five cardiometabolic-related news items have recently been observed: Tandem, Ionis, Esperion, and Amgen hosted their respective Q2 ‘21 earnings calls; and Dario Health announced it was selected as the digital behavioral health provider for an undisclosed national professional services company. Below, FENIX provides highlights and insights for the respective news items.
Novo Nordisk hosted its Q2 ’21 earnings call and provided updates across its commercial and pipeline activities, including the ongoing Wegovy and Rybelsus launches and Novo’s intentions to develop and launch an ASCVD or HF product between 2024 and 2028. Of note, the earnings call was previously scheduled for tomorrow (August 5, 2021), but the company curiously moved it up by a day. Below, FENIX provides highlights and insights from the call.
Two cardiometabolic-related news items have been observed: Abbott announced the Libre 2 iOS app received FDA clearance and Ionis announced the pelacarsen CVOT, called Lp(a) HORIZON, has reached 50% enrollment. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lexicon, Merck, and Intercept hosted their Q2 ’21 earnings calls and provided updates to their respective CV/Met businesses. Below, FENIX provides highlights and insights for the calls.
AstraZeneca hosted its Q2 ’21 earnings call, and once again, much of the prepared remarks and Q&A focused on the company’s COVID-19 vaccine development and oncology portfolio. Below, FENIX provides highlights and insights from the call.
A series of cardiometabolic-related new items have recently been observed: Lifescan and Noom announced an expanded partnership focused on Noom’s Diabetes Support Program; Supersapiens announced the addition of Howard Zisser and Robby Ketchell to the company’s executive team; Teladoc (press release; slides), Pfizer (press release; slides), and Teva (press release; slides) hosted their respective Q2 ’21 earnings calls. Below, FENIX provides highlights and insights for the respective news items.